Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 3/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828868 | 0.90 | KDM4E (0.38) | KDM4EALDH1A1CASP3FPR2IRAK4 | |
| SCHEMBL15447288 | 0.85 | CASP3 (0.49) | HDAC8CASP3IRAK4RAB9ANPC1 | |
| SCHEMBL22452466 | 0.83 | S1PR1 (0.44) | HDAC8KDM4EALDH1A1CASP3IRAK4 | |
| SCHEMBL23320737 | 0.79 | HDAC8 (0.47) | HDAC8KDM4EIRAK4S1PR1HDAC6 | |
| SCHEMBL30886888 | 0.77 | HDAC8 (0.39) | HDAC8PPARARAB9ANPC1 | |
| SCHEMBL29973807 | 0.77 | S1PR1 (0.43) | HDAC8ALDH1A1IRAK4RAB9ANPC1 | |
| SCHEMBL26983072 | 0.75 | HDAC8 (0.38) | HDAC8ALDH1A1IRAK4PPARARAB9A | |
| SCHEMBL23208886 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1FPR2IRAK4MCL1 | |
| SCHEMBL17141092 | 0.75 | CASP3 (0.46) | KDM4EALDH1A1CASP3IRAK4RAB9A | |
| SCHEMBL23348633 | 0.74 | KDM4E (0.43) | HDAC8KDM4EALDH1A1FPR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | HDAC8 2682/4885KDM4E 725/4885ALDH1A1 2830/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | HDAC8 26/4885KDM4E 261/4885ALDH1A1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.